Comparison of Antiplatelet Efficacy and Tolerability of Clopidogrel Napadisilate With Clopidogrel Bisulfate in Coronary Artery Disease Patients After Percutaneous Coronary Intervention: A Prospective, Multicenter, Randomized, Open-Label, Phase IV, Noninfe

In this study of CAD Korean patients who have undergone PCI, the antiplatelet efficacy of clopidogrel napadisilate was noninferior to that of clopidogrel bisulfate after 4 weeks of maintenance treatment. No statistically significant difference was found in tolerability between the 2 treatment groups. ClinicalTrials.gov identifier: NCT01584791.